Cannabis in the Medicine Cabinet from the 1700s to the 1900s

 Long before cannabis became a subject for modern dispensaries, it occupied a very different setting: the medical text, the physician’s casebook, and eventually the pharmacy bottle. Its history includes serious inquiry, ambitious claims, practical frustrations, and political decisions. There were promising observations. There were also conclusions that travelled much further than the evidence carrying them.

This makes the story more interesting than either of its popular shortcuts. Cannabis was neither an unknown plant suddenly discovered by modern medicine nor a perfectly understood remedy that history simply misplaced. Between the 1700s and the end of the 1900s, the ways people described, investigated, and regulated it changed profoundly.

Following those changes reveals something larger about medicine itself. A substance can be familiar long before its chemistry is understood. A physician can recognise a possible effect without knowing its mechanism. And a treatment can appear in a respectable publication without having survived the kinds of trials we would expect today.

The dates matter, but so does the vocabulary surrounding them. When a historical author calls something a remedy, the word tells us what that author believed or observed. It does not automatically carry the meaning of an approved medicine today. Reading the past carefully means resisting the urge to lend it our present assumptions.

The 1700s inherited a much older story

Beginning in the eighteenth century requires looking beyond Europe. Cannabis already belonged to medical traditions with histories extending much further back. Indalecio Lozano’s research on Arabic medical writings examines therapeutic uses recorded between the eighth and eighteenth centuries, including uses associated with pain, nausea, fever, and convulsive conditions. These are records of historical medical practice, not modern confirmation of every claimed benefit. Lozano’s historical study.

That wider perspective matters. Accounts that begin with a European doctor discovering cannabis accidentally erase the people whose knowledge made his investigation possible. Discovery is often an untidy word for the movement of information between communities with unequal access to publication and authority.

The eighteenth century was also an era of botanical classification. Kew’s nomenclatural record traces Lamarck’s Cannabis indica name to a publication in the 1780s. Naming the plant and understanding its medicinal effects were separate projects, but both influenced the vocabulary later physicians encountered. Kew’s record for Cannabis indica.

For a modern reader, this is a useful warning against treating an old plant name as though it were a contemporary product specification. Historical terms belonged to the knowledge and assumptions of their period. Their apparent familiarity can conceal considerable differences in meaning.

A physician in India changed the conversation

William Brooke O’Shaughnessy became an important figure in the nineteenth century history of cannabis medicine through his work in India. His investigations drew on existing knowledge of local preparations and included observations of their effects. His report circulated in British medical literature in 1843, giving physicians a detailed account of a substance many of them had little experience using. O’Shaughnessy’s original publication.

The paper’s title alone reveals the period’s medical priorities. It discusses the effects of Indian hemp and its possible usefulness in tetanus and other convulsive diseases. It belongs to a world in which physicians faced desperate illnesses with limited tools and often learned through individual cases.

That context helps explain the interest without requiring us to endorse the conclusions. A reported change in a patient was a reason to investigate, not proof that a disease had been cured. Symptom relief, recovery, and elimination of an underlying cause are different outcomes. Historical writing needs to keep them separate.

O’Shaughnessy’s importance lies partly in making observations available for others to examine. His work should be read as a chapter in the development of medical inquiry, with both its curiosity and its limitations intact.

Cannabis entered the professional literature

The discussion did not end with one famous report. In 1843, John Clendinning published his own observations on the medicinal properties of Indian cannabis in Medico Chirurgical Transactions. The surviving paper runs across more than twenty pages, a reminder that nineteenth century medical interest was more substantial than a handful of colourful quotations. Clendinning’s original paper.

Reading such publications as historical objects changes the experience. Their importance is not simply whether a modern reader finds a claim persuasive. They show what physicians thought worth recording, which questions they asked, and how they attempted to communicate observations to their peers.

The casebook format also reveals the distance between clinical experience and controlled evidence. Without a suitable comparison group, improvement can be difficult to attribute. Illnesses fluctuate. Other treatments may be involved. A memorable case can become influential precisely because it is memorable, rather than because it represents the usual outcome.

None of this makes the early accounts worthless. It places them in the correct category. They are evidence about medical history and possible starting points for later questions. They are not a prescription waiting to be copied out of an antique journal.

The pharmacy bottle had a consistency problem

By the later nineteenth century, cannabis extracts and tinctures had become part of Western medical practice. Historical research by Antonio Waldo Zuardi describes a period of growing use followed by decline during the opening decades of the twentieth century. One major difficulty was obtaining consistent effects from plant preparations that differed in potency. Zuardi’s history of cannabis as medicine.

For a physician, inconsistency was a practical obstacle. An apparently familiar preparation did not necessarily provide the same experience as the previous one. Before the relevant chemistry could be characterised reliably, the relationship between a product’s identity and its effects remained difficult to pin down. The problem sounds surprisingly modern. Medicine depends on knowing what a patient receives and being able to relate that material to evidence. An attractive label cannot perform that job. Neither can a reputation built around a plant name alone.

The old pharmacy bottle is therefore more than a charming artefact. It represents a central scientific challenge: turning variable biological material into something sufficiently understood and reproducible for clinical use. That challenge did not disappear merely because the bottle looked authoritative on a shelf.

The twentieth century complicated the story

Cannabis medicine did not decline for a single neat reason. Zuardi’s review describes problems with preparations alongside the growing influence of restrictions, including the American Marihuana Tax Act of 1937. Pharmaceutical practice and legal policy were changing together. A story that attributes everything to either scientific failure or prohibition alone leaves out important context.

It is tempting to arrange the history as a morality play, complete with enlightened doctors, foolish officials, and a final triumphant return. The actual record is less accommodating. Some medical questions were legitimate. So were concerns about variability and unwanted effects. Restrictions also shaped what could be supplied and investigated.

For readers today, the useful lesson is to keep different questions separate. Legal status does not establish clinical effectiveness. Historical popularity does not establish safety. Equally, a period of prohibition does not answer every scientific question about a substance. Politics and pharmacology interact, but they are not interchangeable forms of evidence.

Chemistry opened another door

In 1964, Yechiel Gaoni and Raphael Mechoulam published work identifying the structure of the principal intoxicating constituent now known as delta 9 THC. The achievement helped move cannabis research towards defined molecules whose properties could be investigated with greater precision. The original chemistry paper.

The implications extended beyond giving a familiar effect a chemical name. Researchers could ask more specific questions about a particular compound rather than treating every preparation as the same mysterious substance. Precision made disagreement more useful: investigators could begin to establish whether they were even studying comparable material.

Later discoveries shifted attention from the plant towards the body. In 1988, William Devane and colleagues reported evidence characterising a cannabinoid receptor in rat brain. In 1992, researchers identified anandamide, a compound produced in the body that binds to cannabinoid receptors. The receptor study and the anandamide study helped establish a new biological framework for investigation.

By the close of the twentieth century, the scientific conversation had changed. The question was no longer simply what an extract appeared to do. It included the molecules involved, their targets, and the signalling systems researchers were beginning to understand.

What the old medicine cabinet teaches us

For Canadian Seed Bank Blog readers, the value of this history lies in its depth. Cannabis connects traditional knowledge, botanical study, clinical observation, chemistry, and public policy. None of those chapters should be asked to stand in for the entire book.

The strongest conclusion is also the least theatrical. Historical use can justify curiosity. Careful experiments must establish what that curiosity eventually permits us to claim. The medicine cabinet of the past offers a fascinating record of questions being asked. Our responsibility is to keep improving the quality of the answers.